32
Participants
Start Date
June 30, 2014
Primary Completion Date
October 14, 2020
Study Completion Date
October 14, 2020
Ruxolitinib
25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trastuzumab
6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab \> 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
Mount Sinai Medical Center, New York
Columbia University Medical Center, New York
New York Hospital-Weill Cornell Medical Center, New York
Montefiore Medical Center, New York
Collaborators (1)
Incyte Corporation
INDUSTRY
National Cancer Institute (NCI)
NIH
Dawn L. Hershman
OTHER